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Abstract There is a growing belief that the metabolic
program of breast tumor cells could be a therapeutic target.
Yet, without detailed information on central carbon
metabolism in breast tumors it is impossible to know which
metabolic pathways to target, and how their inhibition
might inﬂuence different stages of breast tumor progres-
sion. Here we perform the ﬁrst comprehensive proﬁling of
central metabolism in the MCF10 model of mammary
carcinoma, where the steps of breast tumor progression
(transformation, tumorigenicity and metastasis) can all be
examined in the context of the same genetic background.
The metabolism of [U-
13C]-glucose by a series of pro-
gressively more aggressive MCF10 cell lines was tracked
by 2D NMR and mass spectrometry. From this analysis the
ﬂux of carbon through distinct metabolic reactions was
quantiﬁed by isotopomer modeling. The results indicate
widespread changes to central metabolism upon cellular
transformation including increased carbon ﬂux through the
pentose phosphate pathway (PPP), the TCA cycle, as well
as increased synthesis of glutamate, glutathione and fatty
acids (including elongation and desaturation). The de novo
synthesis of glycine increased upon transformation as well
as at each subsequent step of breast tumor cell progression.
Interestingly, the major metabolic shift in metastatic cells
is a large increase in the de novo synthesis of proline. This
work provides the ﬁrst comprehensive view of changes to
central metabolism as a result of breast tumor progression.
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Introduction
More than 80 years ago Otto Warburg observed that slices
of tumor tissue took up high levels of glucose and produced
high levels of lactate, even under aerobic conditions [1].
His ﬁndings were striking because aerobic conditions
normally support the complete metabolism of glucose to
CO2, not to the production of lactate, leading Warburg to
postulate that tumor cells make use of ‘‘aerobic glycoly-
sis.’’ This metabolic shift is often called the Warburg effect
(or Warburg hypothesis). Many recent observations have
been taken as support for the Warburg hypothesis, and
there is a common perception that tumor cells have a
‘‘sweet tooth’’ because of their increased glycolytic activity
[2]. Another reason for this perception is that tumors in
patients often uptake a large amount of glucose. This fact is
supported by the clinical use of PET scanning with the
tracer 2-[
18F]ﬂuoro-2-deoxy-D-glucose, the most sensitive
and the most accurate method with which to diagnose solid
tumors, including those of the breast [3]. However, glucose
Adam D. Richardson and Chen Yang contributed equally to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s10549-007-9732-3) contains supplementary
material, which is available to authorized users.
A. D. Richardson  J. W. Smith (&)
The Cancer Center, The Burnham Institute for Medical
Research, 10901 North Torrey Pines Road, La Jolla, CA 92037,
USA
e-mail: jsmith@burnham.org
C. Yang  A. Osterman
Inﬂammatory and Infectious Disease Center, The Burnham
Institute for Medical Research, 10901 North Torrey Pines Road,
La Jolla, CA 92037, USA
J. W. Smith
Proteomics Center, The Burnham Institute for Medical Research,
10901 North Torrey Pines Road, La Jolla, CA 92037, USA
123
Breast Cancer Res Treat (2008) 110:297–307
DOI 10.1007/s10549-007-9732-3uptake is biochemically distinct from the process of gly-
colysis. Although the evidence points to an increase of
glucose metabolism in tumors, it does not deﬁnitively
identify glycolysis as the process that is involved.
The metabolic fate of this glucose is not well understood
and there are reasons to question the universality of the
Warburg effect. In 2004, Zu and Guppy [4] systematically
analyzed the literature on the topic and concluded that
‘‘there is no evidence that tumor cells are inherently gly-
colytic,’’ that both normal and tumor cells exhibit broad
ranges of glycolytic dependence, and that the ranges of
values have signiﬁcant overlap. There are also reasons to
be more vigilant about dissecting the individual steps of
glucose metabolism, which were certainly not apparent at
the time of Warburg. His observation spoke only to the
increased lactate production of tumors. It is now clear that
lactate production can be brought about not only by gly-
colysis but also by the pentose phosphate pathway (PPP).
Furthermore, little work has been done on measuring the
ﬂux of glucose into the downstream reactions of central
carbon metabolism. This information is vitally important
because it will reveal how the tumor cell allocates the
available energy. If such comparisons were available for
tumor and normal cells, or even across different stages of
tumor progression, it may be possible to design anti-tumor
therapies targeting appropriate metabolic pathways.
The purpose of the present study was to perform the ﬁrst
comprehensive analysis of carbon ﬂux through central
metabolism in a cellular model of breast tumor progression.
For this purpose we used the MCF10 model of mammary
carcinoma in which progressively more malignant mam-
mary epithelial lines were obtained by transformation and
subsequent cycling as tumors in nude mice [5]. All cells in
the model are derived from the spontaneously immortal-
ized MCF10-A cell line [6] and therefore have essentially
the same genetic background. The model includes the
spontaneously immortalized MCF10 cells; the MCF10-AT
cells, which are a derivative of these cells transformed with
H-ras and that are mildly hyperplastic in vivo [7]; the
MCF10-AT1 cells that yield atypical hyperplasia and car-
cinoma in situ [8], and the metastatic MCF10-CA1a cells
which have the highest tumorigenic potential [9]. The
genetics [10] and proteomics [11] of this model have been
investigated but the metabolic program has not.
A major reason for the paucity of details regarding
breast tumor metabolism has been the lack of appropriate
experimental techniques. Metabolic modeling and ﬂux
analysis has thus far been largely conﬁned to bacterial and
plant systems due to these systems relative simplicity and
scalability. However, with recent advances in spectros-
copy, molecular biology and mammalian tissue culture
techniques the direct investigation of the human cellular
metabolism is becoming possible. We used 2D HSQC-
NMR, GC-MS and enzymatic assays to quantify the
activity of 15 metabolic reactions or pathways, and to
measure the relative abundance of 21 metabolites. From
these analyses, we were able to develop an isotopomer
model of carbon ﬂux through several key metabolic path-
ways in each of the four MCF10 cell lines. The results
show that the ﬁrst step toward tumorigenesis, transforma-
tion, is accompanied by several transitions in central
metabolism. These include of catabolism of glucose
through the pentose phosphate pathway (both the oxidative
and non-oxidative branches), increased synthesis of glycine
and glutathione, increased ﬂux through the TCA cycle and
a substantial increase in fatty acid synthesis and desatura-
tion. The study also reveals a dramatic increase in the
biosynthesis of proline that coincides with the acquisition
of the metastatic phenotype, the ﬁrst reported link between
the acquisition of metastatic capability, and a shift in
central metabolism. To our knowledge, this is also the ﬁrst
study to report on metabolic shifts that accompany distinct
stages of breast tumor progression.
Experimental procedures
Cell culture and sample collection
The MCF10-A cell line was purchased from ATCC
(Manassas, VA). This cell line was deposited there at an
early passage (#39) by the former Michigan Cancer
Foundation (now The Barbara Ann Karmanos Cancer
Institute) as CRL#10317, the lot used in this study. The
MCF10-AT, MCF10-AT1 and MCF10-CA1a cells were
purchased directly from The Barbara Ann Karmanos
Cancer Institute (Detroit, MI) at passage number 29, 19 and
25, respectively. Cells were maintained in supplemented
MEM media (10% v/v Fetal Bovine Serum, 1% v/v anti-
biotic/antimycotic solution (Omega), 1% v/v MEM non-
essential amino acids (Cellgro), 1% v/v MEM vitamins
(Irvine Scientiﬁc), 1 mM sodium pyruvate (Sigma), 2 mM
L-glutamine (Sigma), and 100 ng/ml human EGF (Sigma).
Cells were labeled with [U-
13C]-glucose for NMR analysis
by seeding cells into 150 mm dishes at a density of
approximately 4 · 10
6 cells per dish. At time (t) = 0 h, the
complete MEM was replaced with MEM supplemented
with 1 g/l glucose (Sigma), 0.5 g/l [U-
13C] glucose
(Cambridge Isotope Laboratories), 10% v/v Fetal Bovine
Serum, 1% v/v antibiotic/antimycotic solution (Omega)
and 1% v/v MEM non-essential amino acids (Cellgro),
1% v/v MEM vitamins (Irvine Scientiﬁc) and 100 ng/ml
human EGF (Sigma). The total glucose concentration was
2.5 g/l with 20% [U-
13C] glucose. Sodium pyruvate and
L-glutamine were not included in the labeling media to
minimize the alternative carbon sources for cells. All cell
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123lines were passaged less than 10 times between thawing
and the completion of [U-
13C] glucose labeling.
A sample of the labeling media was taken at t = 0 and
stored as a reference for analysis. Additional samples of the
growth media were collected at 24 and 48 h. Following the
48 h labeling period cells were rinsed with PBS:EDTA,
detached with trypsin and subjected to centrifugation at
500g for 5 min. This procedure yielded pellets containing
approximately 300 · 10
6 cells, which were split into
fractions of 250 · 10
6 cells and 50 · 10
6 cells for NMR
and GCMS analysis, respectively. Cell pellets were stored
at –80 C for subsequent analysis.
Quantiﬁcation of total protein and growth rates
The amount of protein present in each tissue culture sample
was determined using the DC Protein Assay Kit (Bio-Rad).
The assay was performed generally according to the
manufacturer’s protocol in microplate format. Brieﬂy,
2.5 ll of cell lysate was added to 225 ll of reaction mix-
ture and incubated at room temperature for 30 min. The
reaction was via UV absorbance at 650 nm using a Bio-
Rad 3550-UV microplate reader. Each measurement was
performed in triplicate. The protein concentration was
calculated via a Bovine Serum Albumin (BSA) standard
curve (0.25–5 mg/ml; R
2 = 0.9966) and the rate of growth
for each cell line was determined by growth rate = (ln(g
proteint = 48 h) – ln(g proteint=0h ))/48 h.
Quantiﬁcation of glucose consumption and lactate
production
The amount of glucose present in the media samples was
determined using the Glucose Assay Kit (GAGO-20) from
Sigma. The assay was performed generally according to the
manufacturer’s protocol but scaled down to microplate
format. Brieﬂy, 2.5 ll of media was added to 100 llo f
enzyme mixture and incubated at 37 C for 30 min. The
reaction was quenched with 100 ll1 2NH 2SO4 and the
reaction was observed via UV absorbance at 490 nm using
a Bio-Rad 3550-UV microplate reader. Each measurement
was performed in triplicate. The glucose concentration was
calculated via a standard curve (0.25–2.5 mg/ml; R
2 =
0.9973). The rate of glucose consumption for each cell line
was determined by ((mmol glucose =0h ) – (mmol glu-
coset = 48 h))/(48 h((g proteint = 48 h + g proteint=0h )/2)).
The amount of lactate present in the media samples was
determined by generally following the Sigma Diagnostics
Procedure No. 826-UV. All components were purchased
from Sigma. Nicotinamide adenine dinucleotide (10 mg)
was dissolved in 2 ml glycine buffer, 4 ml water and
100 ll lactate dehydrogenase (1000 U/ml). A media sam-
ple (2.5 ll) was added to 145 ll of this enzyme mixture
and incubated at room temperature for 30 min. The level of
lactate was calculated from the observed decrease in
absorbance at 340 nm. Each measurement was performed
in triplicate. The lactate concentration was calculated via a
standard curve (0.25–1.25 mg/ml; R
2 = 0.9997). The rate
of lactate production for each cell line was determined by
((mmol lactate =4 8h ) – (mmol lactatet=0h ))/(48 h((g
proteint = 48 h + g proteint=0h )/2)).
Extraction of cellular metabolites
After the experimental incubations, approximately
2.5 · 10
8 cells were harvested and cell metabolites were
extracted using the cold methanol extraction method. It has
been reported that the cold methanol extraction is superior
to other procedures commonly used for metabolome anal-
ysis, which include acid or alkaline treatments, high-
temperature extraction in the presence of ethanol or
methanol, and extraction with chloroform–methanol [12].
Cell pellets were suspended in phosphate buffered saline,
and L-methionine in an amount of 5 · 10
–6 mol was added
for quantiﬁcation of metabolite concentration and calibra-
tion of chemical shift in the NMR spectra. The cells were
extracted with an equal volume of cold (–20 C) absolute
methanol. After rapid mixing, the tube was transferred into
a dry ice bath for 30 min and subsequently thawed in an ice
bath for 10 min. Cells were subjected to centrifugation
(18,000g, 10 min) and the supernatant was collected. The
cell pellet was subjected to extraction another time with
0.5 ml of 50% v/v cold (–20 C) methanol, and the ﬁrst and
second extracts were combined. The cell extract was
evaporated to dryness, and then dissolved in 650 llo fD 2O
(99.9% enriched; Cambridge Isotope Laboratories). The
sample was ﬁltered through a 0.2-lm-pore-size ﬁlter and
used for NMR measurements.
Analysis of fatty acids by GCMS
The GCMS samples were prepared from about 5 · 10
7
cells as described previously [13]. Brieﬂy, the cell pellet
was saponiﬁed with 1 ml of 30% KOH:ethanol (1:1 v/v) at
70 C overnight. Heptadecanoic acid (C17) in an amount of
1 mg was added as an internal standard. Neutral lipids were
removed with petroleum ether extraction. The aqueous
layer was acidiﬁed by adding 1.25 ml of 2.5 N sulfuric
acid, and then the fatty acids were extracted with 2 ml
petroleum ether. The petroleum ether layer was washed
with Milli-Q water and evaporated to dryness. The fatty
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123acids were methylated with 0.5 N methanolic HCl (Supe-
lco, Bellfonte, PA) and incubated at 65 C for 30 min.
GC-MS measurements were performed on a Trace GC/
Trace MS Plus system (Thermo Electron Corporation,
Waltham, MA). The settings are as follows: ﬂow rate of
carrier gas (helium), 2 ml/min; source temperature, 200 C;
interface temperature, 250 C. The column of Rtx-5MS
(fused silica, 15 m · 0.25 mm · 0.25 lm) (Restek,
Bellefonte, PA) was used for GC-MS analysis. Electron
impact (EI) spectra were obtained at –70 eV. The GC oven
temperature was programmed from 180 C (1 min) to
210 Ca t3  C/min. Palmitate, palmitoleate, stearate and
oleate were monitored at m/z 270, 268, 298 and 296,
respectively.
Mass isotopomer distribution was determined after
correcting the contribution of labeling arising from natural
abundances of carbon (
13C), oxygen (
17O,
18O), and
hydrogen (
2H) [14]. The
13C enrichment of acetyl units and
the de novo synthesis of fatty acids were determined from
the distribution of mass isotopomers of fatty acids. De novo
synthesis produces fatty acids with 2, 4, or 6
13C atoms
(m2,m 4, and m6). Thus the enrichment of acetyl units was
calculated from the m4/m2 or m6/m4 ratio using the formula
m4/m2 =( n – 1)/2  (p/q) and m6/m4 =( n – 2)/3  (p/q),
where n is the number of acetyl units in fatty acids (n =8
for palmitate and palmitoleate; n = 9 for stearate and ole-
ate), p is the labeled fraction, and q is the unlabeled
fraction (p + q = 1). The de novo synthesis was then cal-
culated by dividing the observed to the predicted mass
isotopomer fraction, i.e., m2/(8  p  q
7)o rm 4/(28  p
2 
q
6) for palmitate and palmitoleate, m2/(9  p  q
8)o rm 4/
(36  p
2  q
7) for stearate and oleate.
Identiﬁcation and quantiﬁcation of metabolites by
NMR spectroscopy
NMR experiments were performed at 30 C and 500 MHz
on a Bruker Avance 500 spectrometer (Bruker, Karlsruhe,
Germany). One-dimensional
1H spectra were acquired
using a spectral width of 5000 Hz and 32 K data points.
Two-dimensional [
13C,
1H] HSQC spectra were obtained
using a standard gradient-based sequence. The acquisition
parameters were t1max = 183 ms, t2max = 157 ms; data size
was 3,072 points in t1 and 1,024 points in t2. Sweep width
was 80 ppm and the carrier position was 50 ppm for
13C.
13C decoupling during t2 was achieved using WALTZ-16,
and quadrature detection in x1 was accomplished with
States-TPPI. Before Fourier transformation, the time
domain data were multiplied in t1 and t2 with sine-bell
windows shifted by p/2. The digital resolution along x1
after linear prediction and zero-ﬁlling was 1.23 Hz/point.
The
13C–
13C scalar coupling ﬁne structures were extracted
from the cross sections taken along the
13C axis in a HSQC
spectrum by using the Bruker XWINNMR software. After
manual baseline correction, the individual multiplet com-
ponents of the scalar coupling ﬁne structures were
integrated to quantify the relative contributions of singlet,
doublet, and quartet signals.
The assignments of metabolites in the HSQC spectra
were made according to published data, by comparison
with spectra of authentic compounds, by spiking the sam-
ples and by observing the
13C–
13C scalar coupling ﬁne
structures. Details and chemical shifts are listed in Sup-
plement Table S1. In all, 22 compounds could be identiﬁed
in extracts of the MCF10 series of cells.
The concentrations of metabolites were determined by
integrating the cross peaks in the HSQC spectra using the
NMRPipe and Sparky software packages, comparing with
the integral of resonances peaks of the L-methionine that
was treated as an internal standard, and normalizing to the
amount of total cellular protein (Supplement Table S2). For
each sample, the spectra were recorded twice using the
same acquisition parameters to determine the intra-indi-
vidual variation in the determination of metabolite
concentrations. The signiﬁcance of the various concentra-
tion values was analyzed using Student’s t-test. Probability
values (5%) were taken as signiﬁcant results (P\0.05).
These values are shown throughout the ‘‘Results’’ section
as well as Supplement Table S3.
Isotopomer analysis and modeling
A detailed presentation of the methodology used in the ﬂux
analysis for the pentose phosphate pathway, TCA cycle,
anaplerosis and glutamate–glutathione local network is
presented in the Supplement.
Results
We quantiﬁed key metabolites and carbon ﬂuxes in four
breast epithelial cell lines, allowing us to identify shifts in
central metabolism that coincide with changes in cellular
phenotype. Three types of measurements were made in this
study. First, the basic metabolic parameters (glucose utili-
zation and lactate production) and growth rates were
measured. Second, the relative levels of 22 key metabolites
were determined. These levels are presented as a ratio of
the pool size in one type of cell type to the pool size in
another type of cell. Third, the relative ﬂux of carbon
through 15 different metabolic steps was quantiﬁed
(Figs. 1, 2). Flux was quantiﬁed by comparison of the
isoptopic signature of metabolites that are indicators of
given metabolic hubs [15]. All of the values in this study
300 Breast Cancer Res Treat (2008) 110:297–307
123were normalized to the cells total protein content; there-
fore, increased ﬂux or pool size represent true shifts in the
way the cell is using its resources and are not just a
reﬂection of the rate of proliferation.
Cellular transformation is associated with increased
ﬂux through the pentose phosphate pathway
The early catabolism of glucose takes place in glycolysis or
the pentose phosphate pathway (or both). Consequently,
comparing the relative ﬂux of glucose through each of
these shunts is an important ﬁrst step in tracking glucose
metabolism. To determine the relative ﬂux of each of these
pathways the labeling state of pyruvate must be deter-
mined. However, pyruvate is in relatively low abundance
within human cells and thus is not easily observable by
HSQC in a complex mixture. Fortunately, pyruvate is in
rapid equilibrium with alanine (which is present in much
greater abundance). Therefore we observe the C2 of ala-
nine in order to determine the labeling state of pyruvate
and from these values determined the ﬂux of glucose
through the PPP and glycolysis. Surprisingly, the percent-
age of glucose metabolized through glycolysis is decreased
in the transformed MCF10 cells (MCF10-AT, MCF10-
AT1, and MCF10-CA1a) when compared to the non-
transformed parental MCF10-A cells (Table 1). Nearly all
of the pyruvate is derived from glycolysis in the MCF10-A
cells, but in the transformed cells this value drops to
between 65% and 70%.
The decrease in the fraction of glucose shunted through
glycolysis is more than compensated for by an increase in
net ﬂux through the PPP to pyruvate (Fig. 3). The non-
transformed MCF10-A cells catabolized only a minor
fraction of glucose via the PPP, but the transformed
MCF10-AT cells catabolized approximately 30% of the
glucose through this pathway. Flux through the PPP to
pyruvate is similarly elevated in the more aggressive the
MCF10-AT1 and MCF10-CA1a cells (Table 1). However,
the conversion of glucose to pyruvate is only one of the
possible ‘‘directions’’ of the pentose phosphate pathway.
The non-oxidative branch of the PPP converts the glyco-
lytic intermediates fructose-6-phosphate and
glyceraldehydes-3-phosphate to ribose-5-phosphate, com-
plementing the oxidative branch in the production of this
nucleotide precursor. The relative ﬂux through each branch
of the PPP was gauged by using the C2 of UDP as an
indicator (see Supplement for explanation). In comparison
to the non-transformed MCF10-A cells, all three trans-
formed MCF10 cells show a pronounced increase in ﬂux
through the oxidative branch of the PPP. The proportion of
ribose generated through this branch is almost double in the
MCF10-AT cells compared to the MCF10-A cells (30% of
the total ﬂux through PPP versus 16% of the total).
Flux through the TCA cycle is higher in tumorigenic
cell lines
The relative ﬂux through the TCA cycle in each cell line
was measured using the isotopomer labeling of glutamate
as an indicator (see Supplement II for explanation). Results
showed the TCA cycle ﬂux was increased approximately
1.8-fold in the transformed cells compared to the
Fig. 1 Metabolites, ﬂuxes and pathways quantiﬁed in the MCF10
tumor progression model. Metabolites presented in the shaded boxes
were observed by NMR, GCMS or enzymatic assay. Abbreviations are
G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; R5P, ribose-5-
phosphate; GAP, glyceraldehydes-3-phosphate; 3PG, 3-phosphoglyc-
erate; KG, a-ketoglutarate; GSH, glutathione; GlcNAc, N-
acetylglucosamine;PC,phosphocholine;GPC,glycerophosphocholine
Fig. 2 Metabolic ﬂuxes and pathway activities determined by
isotopomer analysis or enzymatic assay. Flux 1: glucose import; 2:
glycolysis; 3: pentose phosphate pathway; 4: lactate excretion; 5:
pyruvate dehydrogenase ﬂux; 6: TCA cycle ﬂux; 7: pyruvate
carboxylase ﬂux; 8: gluconeogenic ﬂux; 9: glycine biosynthesis; 10:
glutathione biosynthesis; 11: proline biosynthesis; 12: palmitate
biosynthesis (fatty acid synthase activity); 13: desaturation of
palmitate; 14: elongation of palmitate; 15: desaturation of stearate
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123MCF-10A cells (Table 1). This ﬂux, along with other TCA
cycle-related results, is illustrated in Fig. 4. Additionally,
our methodology can observe the gluconeogenic ﬂux from
malate to pyruvate via malic enzyme. This pathway was
not active in any of the four cell lines however and is thus
represented as an open arrow. A recent report by Forbes
et al. reported a similar lack of malic enzyme activity in
MCF7 breast cancer cells [16]. In our analysis of individual
metabolites, we noticed a major change in succinate, a key
metabolite in the TCA cycle. In the transformed cells, the
pool of succinate is substantially increased (Fig. 4). The
degree of the increase in succinate could not be precisely
determined because the pool size is so low in the non-
transformed MCF10-A cells. Nevertheless, the change was
estimated to be at least 5-fold.
Flux through Glycine–Glutamine hub is dramatically
increased in metastatic cells
The glycine–glutamine hub involves the inter-conversions
of glycine, glutathione, glutamate, glutamine and proline.
The entry point for carbon into this hub is the conversion of
3-phosphoglycerate to serine (an irreversible step), which
Table 1 Metabolic parameters quantiﬁed in the MCF10 progression series of breast cancer cell lines
Parameter MCF10-A MCF10-AT MCF10-AT1 MCF10-CA1a
Glucose-pyruvate (Fig. 2) Growth rate (mg/g/h)
a 10 ± 2 20 ± 1** 20 ± 1** 18 ± 1***
Glucose uptake rate (mmol/h/g protein)
a 0.8 ± 0.1 1.0 ± 0.2 1.1 ± 0.2 1.7 ± 0.1***
Pyruvate from glycolysis (%) 98 ± 2 68 ± 7** 65 ± 7** 70 ± 6**
Pyruvate from PPP
b (%) 2 ± 2 32 ± 7** 35 ± 7** 30 ± 6**
Ribose synthesized form oxidative PPP
b (%) 12 ± 3 21 ± 4* 21 ± 4* 24 ± 4*
Lactate excretion rate (mmol/g protein)
a 3.0 ± 0.6 3.4 ± 0.4 2.9 ± 0.3 2.9 ± 0.1
Intracellular lactate (rps
c) 1 2.33 ± 0.48* 1.68 ± 0.34* 1.96 ± 0.40*
Alanine (rps
c) 1 2.54 ± 0.38** 1.89 ± 0.27** 1.08 ± 0.10
TCA (Fig. 3) Relative TCA cycle ﬂux
a 1 1.8 ± 0.2** 1.7 ± 0.2** 1.4 ± 0.1*
Relative anaplerotic ﬂux
a 1 2.0 ± 0.2** 2.0 ± 0.2** 1.8 ± 0.2**
Succinate (rps
c)1 [5.26** [5.13** [5.29**
Fatty acids (de novo) Palmitate (%) 1.9 ± 2.0 51.7 ± 2.9*** 43.4 ± 0.5*** 40.1 ± 0.3***
Palmitoleate (%) 0 ± 2.0 35.5 ± 4.9** 7.3 ± 0.7* 0.6 ± 0.8
Stearate (%) 1.7 ± 2.1 35.9 ± 4.5** 34.2 ± 1.1*** 29.2 ± 3.0**
Oleate (%) 0 ± 2.0 25.3 ± 2.6** 13.0 ± 4.8** 13.3 ± 1.2**
Glutamate hub (Fig. 4) Glutamate (rps
c) 1 1.22 ± 0.24 1.37 ± 0.21 0.72 ± 0.11
Glutamine (rps
c) 1 0.65 ± 0.11* 0.60 ± 0.10* 0.19 ± 0.04**
Glutathione (rps
c) 1 1.00 ± 0.07 1.20 ± 0.10 0.78 ± 0.06*
Glycine (rps
c) 1 0.59 ± 0.08* 0.62 ± 0.09* 0.40 ± 0.06**
Proline (rps
c) 1 0.72 ± 0.14 0.82 ± 0.13 1.43 ± 0.26
Glutathione ﬂux (relative)
a 1 4.2 ± 0.6** 4.9 ± 0.8** 2.5 ± 0.4**
Glycine ﬂux (%)
a 2 ± 2 12 ± 2* 21 ± 4** 24 ± 4**
Proline ﬂux (%)
a 0±2 0±2 0±2 5 2±6
The table contains information on the overall metabolic status of the cell, ﬂux through metabolic pathways and the pool size of individual
metabolites
a The overall metabolic state of the cells including growth rate, glucose uptake and lactate excretion are calculated per gram of total protein per
hour
b Flux toward a given metabolite is calculated as a percentage of the total production of that metabolite from
13C-glucose through the given
pathway
c In other cases information on the synthesis of a metabolites is presented relative to the same ﬂux in the MCF10A cells. This distinction is made
because the metabolite is predominantly generated from
13C-glucose through a single pathway (alternative routes of production are not evident)
d The relative size of the cellular pool of these metabolites is shown as a ratio to the same metabolite in the MCF10A cells
e Fatty acid composition was measured by GC-MS and is presented as a percentage of the de novo synthesis of each fatty acid from
13C glucose
f See ‘‘Materials and methods’’ for calculations
g PPP = pentose phosphate pathway
h rps = relative pool size
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123is then converted to glycine. Flux through this ﬁrst step was
measured by direct assessment of the isotopic signature of
glycine. Interestingly, ﬂux toward glycine exhibits a
striking step-wise increase in each of the MCF10 cells as
they become more aggressive (Table 1). Flux into this hub
step is 12-fold higher in the MCF10-AT cells than in the
normal MCF10-A cells; in the metastatic MCF10-CA1a
cells, the ﬂux is 24-fold higher.
Interestingly, although the biosynthesis of glycine
increased in these transformed cells, its pool size actually
decreased because it is rapidly consumed for glutathione
synthesis. Flux from glycine to glutathione is higher in all
tumor cells compared to the MCF10-A line, but there is no
corresponding increase in the size of the glutathione pool
(Fig. 5). Rather, we observe increases in the pool sizes of
glutamate or proline. The size of the glutamate pool is four
to ﬁve times larger in the MCF10-AT and MCF10-AT1.
However, in the metastatic MCF10-CA1a cells, the size of
the glutamate pool is smaller than in the MCF10-A cells.
The smaller size of this pool is probably the result of
increased biosynthesis of proline, a step for which gluta-
mate is the key precursor. Flux to proline is at least 50-fold
higher in the MCF10-CA1a cells than in the MCF10-A
cells. Despite the substantial differences in ﬂux toward
proline in all of these cells, there is only a slight increase in
the size of the pool of proline, indicating that this amino
acid is used rapidly.
Fatty acid synthesis is elevated in the transformed cell
lines
GC/MS was used to quantify the
13C labeling of fatty acid
species. From this value we can infer the percent of the
total pool of each fatty acid that is
13C labeled, and thus the
relative levels of de novo synthesis of each fatty acid. Four
fatty acids were examined, palmitate (16:0), which is
synthesized by fatty acid synthase, and palmitoleate (16:1),
stearate (18:0) and oleate (18:1), which are derived from
the desaturation and/or elongation of palmitate. The
MCF10-A cells synthesized very little of the four fatty acid
species (Table 1). However, de novo synthesis of palmitate
increased 10-fold in the transformed MCF10-AT cells, and
was elevated to similar levels in the other two tumorigenic
cell lines. De novo synthesis of stearate and oleate were
also elevated in all of the tumorigenic MCF10 lines in
comparison to the MCF10A cells. The exception to this
pattern was the de novo synthesis of palmitoleate, which
was only substantially elevated in the transformed MCF10-
AT cells. These observations show rather substantial
changes to the fatty acid hub, and suggest that several
Fig. 3 Relative distribution of the glucose-pyruvate local network in
MCF10 cells. Flux through the pentose phosphate pathway increases
as cells become progressively more tumorigenic. Observed metabo-
lites are boxed in grey and their relative sizes between tumorigenic
states are roughly proportional to the observed pool sizes. Observed
ﬂuxes are shown as grey arrows and their widths are roughly
proportional to the relative pathway ﬂux. See Table 1 for values.
Normal is the MCF10-A cells; transformed is the MCF10-AT cells;
metastatic is the MCF10-CA1a cells. G6P = glucose-6-phosphate;
F6P = fructose-6-phosphate
Fig. 4 Relative distribution of the TCA cycle in MCF10 cells. Flux
through the TCA cycle and the pool size of succinate are higher in
tumorigenic cells than in untransformed cells. Observed metabolites
are boxed in grey and their relative sizes between tumorigenic states
are roughly proportional to the observed pool sizes. Observed ﬂuxes
are shown as grey arrows and their widths are roughly proportional to
the relative pathway ﬂux. See Table 1 for values. Normal is the
MCF10-A cells; transformed is the MCF10-AT cells; metastatic is the
MCF10-CA1a cells. a-KG = a-ketoglutarate
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123enzymes in this pathway may be linked to breast tumor
progression.
Discussion
The objective of this study was to identify changes in
glucose metabolism that are associated with cellular
transformation and acquisition of tumorigenic and meta-
static potential in breast epithelial cells. The MCF10 panel
of cell lines are an attractive system for such studies as they
are a stable and well-characterized tissue culture model of
mammary tumor progression. In order to minimize artifacts
due to external components, a minimal common media was
designed and used for all four cell lines investigated. The
MCF10-A cell line requires growth factors to proliferate in
two-dimensional culture, while the other MCF10 cell lines
used here respond to such factors but do not require them
for growth [5, 7]. However, the standard MCF10 media
formulation contains a number of components which have
the potential to alter cellular metabolism, including insulin
[17]. We developed a MEM-based, glucose-centric media
supplemented with EGF in which all four cell lines dis-
played continual proliferation over the 48 h
13C-glucose
labeling period. We believe that growing each of the cell
lines on this common background during log-phase growth
has minimized any potential metabolic variation due to
differential responses to media factors, basal proliferation
rate and cell cycle stages.
Thus a comprehensive 2D HSQC NMR and GC-MS
proﬁling strategy was used to characterize the metabolic
program of the MCF10 model of mammary carcinoma and
to determine if the ﬁndings support the Warburg effect or
suggest another explanation for the uptake of glucose and
increased lactate production in cancer cells. The trans-
formed phenotype is accompanied by (1) increased
catabolism of glucose by the pentose phosphate pathway
(both oxidative and non-oxidative), (2) an increase in ﬂux
through the TCA cycle and a corresponding increase in the
cellular pool of succinate, (3) increased ﬂux through the
glycine–glutamine hub and a corresponding increase in
glutamate, and (4) a substantial increase in fatty acid
synthesis and oxidation. These alterations are essentially
stable through additional transitions in tumor cell pheno-
type and are evident in metastatic cells. Perhaps equally as
signiﬁcant though, the study reveals that acquisition of the
metastatic phenotype is associated with a massive increase
in the biosynthesis of proline. To our knowledge, this is the
ﬁrst study to take a comprehensive and comparative
approach toward the links between breast tumor progres-
sion and metabolism, and the ﬁrst study to characterize the
metabolome of the metastatic cell.
Our results on glucose uptake and lactate excretion, the
two parameters discussed by Warburg, are only partially
consistent with his hypothesis. We do observe a doubling
of glucose uptake in the metastatic MCF10-CA1a cell line
when compared to the non-tumorigenic MCF10-A cells.
Increases in glucose uptake were also observed in the less
aggressive MCF-10AT and MCF-10AT1 cells, although
the magnitude of these increases was small relative to the
other tumor cell lines. However, we did not observe any
consistent trend toward increased production of lactate by
Fig. 5 Relative distribution of the glutamate–glutathione hub in
MCF10 cells. Flux through the glycine–glutamine hub is higher in
tumorigenic cells than in normal cells. Dramatic increases in the
biosynthesis and pool size of proline coincide with the acquisition of
the metastatic phenotype. Observed metabolites are boxed in grey
and their relative sizes between tumorigenic states are roughly
proportional to the pool sizes observed. Observed ﬂuxes are shown as
grey arrows and their widths are roughly proportional to the relative
pathway ﬂux. See Table 1 for values. Normal is the MCF10-A cells;
transformed is the MCF10-AT cells; metastatic is the MCF10-CA1a
cells; a-KG = a-ketoglutarate
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123the tumor cells compared to the MCF10-A cells. This is
most likely due to two factors: the immortalization of the
MCF10-A cell line and the necessities of two-dimensional
tissue culture. The MCF10-A cell line has a karyotypic
gain of MYC, IL4 and IL12B concurrent with a homozy-
gous loss of CDKN2BA and CDKN2B [10]. Cytokines have
been shown to generally stimulate glycolysis (speciﬁcally,
IL-3, IL-7 and IL-2) and increase the amount of lactate
produced per glucose unit consumed [18]. Additionally, the
MCF10A cell line requires EGF, which has also been
shown to increase glycolysis [19]. Thus the relatively high
lactate production in the MCF10-A cell line is most likely a
result of the required tissue culture conditions.
However, our ﬁndings indicate that the distinctions
between the tumorigenic and non-tumorigenic cell lines
really center on how glucose is used and how carbon from
glucose is shuttled through central carbon metabolism. The
comprehensive strategy employed in the present study
allowed an assessment of carbon ﬂux through both the
oxidative and non-oxidative branches of the PPP, each of
which have two outputs—pyruvate and ribose. However,
the oxidative branch has the additional role of synthesizing
cellular NADPH, which is the primary source of reducing
power of the cell. Flux through both branches of the PPP is
increased in transformed cells, and the fact that ﬂux
through the non-oxidative branch is increased is consistent
with the observations in different tumor cell lines [16, 20,
21]. Perhaps more interestingly, the magnitude of the
increase in ﬂux is higher for the oxidative branch. The
increase in ﬂux through the oxidative branch is probably a
reﬂection of the ampliﬁed need of the transformed cells for
the reducing power of NADPH, which is used for many
biosynthetic reactions and is involved in protecting the
rapidly proliferating cell from reactive oxygen species
through glutathione. The increased ﬂux through the oxi-
dative branch also has potential implications for anti-tumor
therapy. Many common chemotherapeutics act by inducing
oxidative stress [22–26], which could be counteracted by
the reducing power produced by the oxidative branch of the
PPP. Therefore, drugs that independently inhibit the oxi-
dative branch of the PPP may reduce the ability of the
tumor cell to protect against oxidative stress brought on by
chemotherapy.
The increased activity of the PPP also supports
increased synthesis of nucleotides, which are in increased
demand in highly proliferative tumor cells. Flux through
each branch of the PPP can provide ribose-5-phosphate and
then 5-phosphoribosylpyrophosphate, a key nucleotide
precursor. The production of nucleotides also requires
tetrahydrofolate, which is synthesized from glycine. Thus
the reduction in the glycine pool size may relate to the fact
that glycine donates methylene units to tetrahydrofolate.
Glycine can also be converted to glutathione, which in turn
can be converted to glutamate and then to proline. The
increased ﬂux through the PPP and the glycine–glutamine
hub as cells become more tumorigenic is therefore critical
because of the signiﬁcant demand placed upon nucleotide
synthesis during transformation.
Two key alterations in the TCA cycle were also
observed in the H-ras transformed MCF10-AT cells; these
alterations persisted in cells with increased hyperplasticity
and metastatic potential. The changes include a near dou-
bling of ﬂux through the TCA cycle, and a corresponding
increase in the size of the succinate pool. The exact size of
the increase in the succinate pool could not be determined
because the pool size is extremely low in the non-trans-
formed MCF10-A cells. Nevertheless, we have determined
the change to be at least 5-fold. This ﬁnding should be
interpreted in the context of recently published work
showing that high levels of cellular succinate can inhibit
HIF-1a prolyl hydroxylase, and thereby cause a pseudo-
hypoxic cellular response [27]. Such a response is expected
to activate genes under the control of HIF-1a and thereby
promote a tumorigenic phenotype. In fact, germline
mutations in either fumarate hydratase or succinate dehy-
drogenase can drive this event and lead to a predisposition
to tumors [28]. Therefore, the increased levels of succinate
in the transformed MCF10-A cells may actually contribute
to their tumorigenicity. The mechanisms underlying the
increase in the succinate pool are not readily apparent. It is
unlikely that inhibition of succinate dehydrogenase is
involved in the transformed MCF10 cells because the total
ﬂux through the TCA cycle was increased. Thus, there is
the distinct possibility that an increase in TCA cycle ﬂux
independently drives an increase in the succinate pool,
which in turn could increase the level of HIF-1a. In other
systems, such a connection between glycolysis and HIF-1a
levels has been proposed, although succinate was not
involved [29].
In this study two major alterations were observed in the
glycine–glutamate hub. First, in the transformed cell lines
displayed a 2- to 4-fold increase in the ﬂux of carbons
through GSH (indicating greater GSH turnover). This
increase in ﬂux through GSH is observed even as the size
of the GSH pool decreases, indicating that increased
demand for GSH in the metastatic cell is greater that the
cell is able to replenish via de novo synthesis. Much like
the results concerning the pentose phosphate pathway
(which provides the NADPH needed for glutathione
reduction), these ﬁndings demonstrate the signiﬁcant
demand placed upon cellular redox buffering during
tumorigenic transformation. Second, we observed a sub-
stantial increase in the ﬂux from glucose to proline in the
MCF10-CA1a cell line. To our knowledge this is the ﬁrst
report of increased proline biosynthesis in metastatic can-
cer cells, which could be connected to increased turnover
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123of the extracellular matrix in metastatic cells. Since tumor
cell invasion is linked to increased degradation of collagen,
one might also presume that as tumor cells invade they
must replenish the digested extracellular matrix in order to
adhere. This process would require increased synthesis of
collagen and thus, since collagen is proline rich, a greater
need for proline. There are few if any studies that examine
the collagen synthesis by tumor cells, but the ﬁnding pre-
sented here indicate that this process should be the topic of
future study.
Finally, these ﬁndings are consistent with our own
observations for another pathway, the synthesis of fatty
acids in breast tumor cells. There is a large body of work
showing that fatty acid synthase (FAS) is up-regulated in a
wide range of cancers [30] and that inhibition of FAS can
halt tumor cell proliferation and induce tumor cell death
(for review see [31]). In fact, we have reported that
Orlistat, a drug approved for obesity, is an inhibitor of
fatty acid synthase and that this drug elicits cell death in a
number of breast tumor cell lines [32]. Not only are the
ﬁndings of the present study consistent with these prior
observations but they also add another dimension. Each of
the fatty acids is derived from either elongation or
desaturation (or both) of palmitate by the action of stea-
royl-CoA desaturases and long chain fatty acid elongase.
Both stearoyl-CoA desaturase [33] and long chain fatty
acid elongase [34] are part of the SREBP-regulated lipo-
genic program that is often activated in solid tumor
progression [35]. Increased stearoyl-CoA desaturase
expression and activity results in increased mono-unsatu-
rated fatty acid (MUFA) levels and this increase in
MUFAs is associated with cancer risk [36] and mecha-
nistically may help modulate membrane ﬂuidity [37], and
anchorage-independent growth [38] in tumor cells. The
fact that tumor cells convert the newly synthesized
palmitate to other fatty acids also suggests that stearoyl-
CoA desaturases and fatty acid elongase should be
explored as potential drug targets.
To our knowledge, this is the ﬁrst study to take a
comprehensive and comparative approach toward the links
between breast tumor progression and metabolism, as well
as the ﬁrst study to characterize the metabolome of the
metastatic cell. The results provide an essential foundation
for subsequent interrogation of individual metabolic steps,
and for gauging the requirement of each step in tumor cell
progression. The analysis provides important information
that will help guide the interpretation of studies of breast
tumor metabolism under hypoxic conditions and studies of
the metabolism of whole tumors in vivo, which are com-
prised of multiple cell types. It also provides a rationale for
using metabolomics for cancer detection and diagnosis, as
well as for the development of novel therapeutics that
speciﬁcally target the tumor cell metabolome.
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